Clinical Trial

The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

Study acronym: RECORD-IQ
Recruiting
View on ClinicalTrials.gov →
Summary
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.
Protocol Amendment History 3 changes
notable Trial sites expanded: 17 -> 21 locations 2026-05-02
notable Trial sites expanded: 13 -> 17 locations 2026-04-24
notable Trial sites expanded: 5 -> 13 locations 2026-04-03
Trial Details
NCT Number NCT07211126
Lead Sponsor Tandem Diabetes Care, Inc.
Conditions Diabetes Mellitus, Type 1
Enrollment 350 participants
Start Date 2026-03-03
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-01